OBJECTIVE: To examine the effect of diet with exercise on serum leptin and whether leptin is associated with the metabolic syndrome X in a high risk population such as overweight postmenopausal women. STUDY DESIGN AND SUBJECTS: 121 healthy overweight, postmenopausal women (aged 49±58 y, body mass index (BMI) 25±42 kgam 2 ) were randomized to: A low-energy-diet, 4.2 MJad (n 51), low-energy-diet standardized physical exercise (n 49) or no intervention (control: n 21) for 12 weeks, followed by 6 months follow-up without intervention. MEASUREMENTS: S-leptin was measured by Radio Immuno Assay (RIA), body composition and fat distribution by dual energy X-ray absorptiometry (DEXA) and anthropometry. Factors associated with the metabolic syndrome X and sex hormones were measured. RESULTS: S-leptin was two-fold higher than in normal-weight postmenopausal women and S-leptin was normalized after weight loss induced by the 12-week low-energy-diet, without any additive effect of the exercise. Of the factors associated with the metabolic syndrome X, serum-leptin correlated signi®cantly only with sex-hormone-bindingglobulin and plasminogen-activator-inhibitor-1, whereas factors associated with obesity per se correlated signi®cantly with leptin. Changes in S-leptin correlated with changes in fat tissue mass during the follow-up, but not during the intervention. S-leptin at baseline did not correlate with either short term or long term weight loss. CONCLUSION: There is no effect of exercise added to diet on S-leptin in overweight postmenopausal women. Leptin does not seem to be associated with the metabolic syndrome X, but rather with fatness. S-leptin is probably associated with both dynamic and static effects of adipose tissue. S-leptin did not predict weight loss.
Introduction
Leptin, the ob gene product, is an adipocyte-speci®c protein with hormone-like properties, which has been found to in¯uence body weight by regulating eating and exercise behavior in mice. (1±3) Despite intensive research the physiological actions of leptin on humans remain unclear and it is not known if leptin plays any pathogenic role in human obesity. The observations on leptin in obesity of humans, are so far opposite to the observations of obese mice, where leptin is low. Recent reports 4±7 on the serum levels of leptin in obese and normal-weight humans showed that the serum level of leptin re¯ects the amount of body fat and that weight loss reduces the level of leptin. Resistance to leptin actions in obese humans was suggested as an explanation of the elevated levels of leptin in these patients. (4, 8) We have previously shown in a randomized intervention study, that exercise in addition to an energy restrictive diet in overweight postmenopausal women was associated with increased loss of fat tissue mass (FTM) compared to diet-alone. 9 In frozen samples from this study we wanted to examine the response of serum leptin due to diet with or without added exercise. A secondary aim was to examine whether leptin is associated with factors which have been linked to the metabolic syndrome X, that is, sex hormones, fat distribution, S-lipids, blood pressure and ®brinolysis, within a high risk population such as overweight postmenopausal women. 10 and randomized into three groups for 12 weeks of intervention: A control group (n 21), a diet-only group (n 51) and a diet-plus-exercise group (n 49) as described in detail in our previous paper. 9 Brie¯y, the diet consisted of the formula diet NUPO (Oluf Mùrk Biochemie, Rùdovre, Denmark) supplying 1.6 MJad. In addition to this, 2.6 MJad from foods freely chosen according to a counter-diet system were allowed. The exercise program consisted of supervised aerobic exercise (bicycling, stair walking or treadmill running with a heart rate above the level corresponding to 70% of the maximal oxygen uptake (VO 2 -max)) and resistance weight training (2±3 periods of eight exercises, including all major muscle groups, with 7±15 repetitions of each exercise with a load of 65% of maximum weight-lifting capacity) for 1 hr, increasing to 1. The 118 women completing the 12-weeks intervention were encouraged to continue dieting and exercise, but were otherwise left unattended. After six months, all women, except eight who were excluded for various reasons, 10 were examined again [Changes during follow-up (mean AE s. 
Methods

Measurements
S-leptin was measured in 780
C frozen serum-samples from baseline, after the 12 weeks of intervention and after the 6 months of follow-up. A commercially available Radio Immuno Assay (Human leptin RIA kit, Linco Research, Inc., St. Charles, Missouri, USA) was used for the leptin determinations. The mean of double determinations was used for the calculations (intra-assay CV%: 5% and inter-assay CV%: 10%).
All other methods are described in the previous papers.
9±11 All blood samples and urine samples were collected after at least 12 h overnight fasting.
Calculations
The abdominal-to-total-body FTM ratio, the WHR and the visceral adipose tissue area (VAT), calculated from the formula: VAT ( Biochemical data were log-transformed, after which they were normally distributed. Two-sided ttests were used for comparisons. The level of signi®cance for the comparisons was determined to be P`0.05. To avoid mass signi®cance problems in the correlation and regression analysis, the level for considering a r value signi®cant was reduced to 0.01. In the correlation analysis, Spearman correlation coef®-cients were calculated when non-normally distributed parameters were involved. Stepwise regression analysis, with S-leptin at different times as dependent variable and FTM and changes in FTM as independent variables were performed to evaluate the static and dynamic in¯uence of FTM on S-leptin. Furthermore to avoid the effects in the correlation and regression analysis of no change in the control group and major changes in the intervention groups the control group was excluded in these analyses and the intervention groups were pooled. For simplicity, even non-normally distributed data are presented as mean AE s.d.as.e.m. The statistical system (SAS Institute Inc., Cary, NC, USA) was used for all statistical analysis.
Results
The S-leptin concentrations at baseline were signi®-cantly higher in the overweight than in the normal weight age-matched postmenopausal women, whose mean AE s.d. values were 10.0 AE 6.6 ngaml (Figure 1 ). Figure 1 furthermore shows the changes of S-leptin over terms. The differences in the changes between the three groups were signi®cant (ANOVA: P`0.001), but no differences were found between the two intervention groups. Compared to baseline, Sleptin decreased by approximately 60% to the level of the normal weight age-and menopause-matched women during the intervention and increased again by approximately 30% during the follow-up, but was still lower than at baseline (P`0.001). Figure 2 shows the r values from the baseline correlations of S-leptin with the body composition parameters, sex hormones and other risk factors for cardiovascular disease. High correlation coef®cients were found with FTM, weight and BMI. However most of the factors which have been associated with the metabolic syndrome X, did not correlate signi®-cantly with S-leptin.
No signi®cant relationship between changes in FTM and changes in S-leptin in the intervention period was found when the control group was excluded from the analysis (r 0.15, P b 0.1). However the correlation of the change in FTM and the change in S-leptin during the observation period (12 weeks±9 months) was signi®cant (r 0.59, P`0.001) (Figure 3 ) and of the same magnitude as the baseline correlation of S-leptin with FTM, as was the correlation of the change in S-leptin and the change in FTM during the whole trial (baseline to 9 months) (r 0.57, P`0.001)(not shown). Table 1 shows the r 2 values from the linear regression analysis of S-leptin, as dependent variable and FTM and the changes in FTM as independent variables. The changes in FTM prior to the measurement of S-leptin always contributed signi®cantly (partial r 2 values: 0.20±0.37, P`0.001) to the models, which all obtained total r 2 values around 0.7. S-leptin at baseline was neither correlated with the changes in FTM during the intervention (r 0.24, P 0.018), nor the changes in FTM during the follow-up (r 70.02, P 0.83), or the changes during the whole study (0±9 months) (r 0.12, P 0.26). S-leptin after the intervention was not correlated with the changes in FTM during the follow-up (r 0.12, P 0.24).
Discussion
Diet and the combination of diet and physical exercise are major interventions in the management of obesity. The physical exercise program used in this study was intensive, thus the VO 2 -max increased 25% in the diet exercise group as compared to the diet-only group 9 and furthermore only a few subjects dropped out. We found, however, no effect of physical exercise in addition to diet on the S-leptin concentrations in overweight postmenopausal women, which is also in accordance with the ®ndings of Kohrt et al. 7 Thus, even intensive physical exercise does not affect Sleptin beyond the effect of diet alone ± despite a greater loss of fat in the exercise group. This suggests that the energy restrictive dietanegative energy balance, rather than the loss of fat might be responsible for the change in S-leptin. Short term negative energy balance has been shown to induce acute changes to the S-leptin level 13 and since the blood samples at the 12 week visit were taken just before patients were allowed to change their diet, the S-leptin values after 12 weeks might re¯ect an overall negative energy balance. A recent hypothesis by Sùrensen et al, 14 which suggests that S-leptin might re¯ect the dynamics of the adipocytes ± for instance the accumulation of fat in the adipocytes ± rather than simply the size of the adipose tissue, can explain the diverging association between the changes in fat and the changes in S-leptin during the intervention and during the observation found in our study. Thus, with severe energy restriction and loss of fat during the intervention, the production of leptin is decreased perhaps to a basal static level. When the energy balance is then changed and fat accumulation begins, S-leptin increases as a result of increased production in the adipocytes. The theory is also supported by the fact that the dynamics of the adipose tissue, measured as the changes in FTM, prior to measuring S-leptin, consistently contributed to the regression models explaining the variance of S-leptin at a given time (Table 1) . We therefore (as Sùrensen et al 14 ) suggest that, apart from the size of the adipose tissue alone, a dynamic factor in the adipose tissue, which maybe re¯ects the energy balance, is involved in determining the Sleptin concentrations.
From the baseline correlations we found that Sleptin primarily was associated with FTM. This is in accordance with others, 4±7 though they found higher r values. This could be due to their subjects representing a greater range of FTM (pooling normal weight and overweight subjects) than our overweight postmenopausal women. Thus, when we included the 22 normal weight age-matched postmenopausal women, the correlation of S-leptin with FTM at baseline increased from r 0.64 to r 0.77.
Except for sex-hormone-binding-globulin and plasminogen-activator-inhibitor-1, none of the factors associated with the metabolic syndrome X were associated with S-leptin. Neither the abdominal-tototal-body FTM ratio, the WHR or the estimated visceral adipose tissue area were associated with leptin. Thus the theory about leptin re¯ecting thè metabolic active' intra abdominal adipose tissue, cannot be con®rmed by our study. On the other hand, signi®cantly higher correlations were found between S-leptin and obesity parameters per se, namely FTM, weight and BMI. Thus, in a group of healthy overweight postmenopausal women, who are at high risk for cardiovascular disease and non-insulin-dependent diabetes mellitus, leptin does not seem to be associated with the metabolic syndrome X, but rather with overall fatnessaobesity. Figure 3 Relationship between changes in FTM and changes in S-leptin during the 12 weeks intervention (baseline to 12 weeks) and the 6 months follow-up (12 weeks to 9 months). (r 0.57, P`0.001 for the correlation between changes in S-leptin and changes in FTM from baseline to 9 months). 
